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Abstract
In recent years otolaryngology was strongly influenced by newly de-
velopedimplantswhicharebasedonboth,innovativebiomaterialsand
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novel implant technologies. Since the biomaterials are integrated into
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biological systems they have to fulfill all technical requirements and
accommodate biological interactions. Technical functionality relating
to implant specific mechanicalproperties, a sufficiently high stability in
terms of physiological conditions, and good biocompatibility are the
demands with regard to suitability of biomaterials. The goal in applying
biomaterials for implants is to maintain biofunctionality over extended
periods of time. These general demands to biomaterials are equally
valid for use in otolaryngology. Different classes of materials can be
utilized as biomaterials. Metals belong to the oldest biomaterials. In
addition,alloys,ceramics,inorganicglassesandcompositeshavebeen
tested successfully. Furthermore, natural and synthetic polymers are
widely used materials, which will be in the focus of the current article
with regard to their properties and usage as cochlear implants, osteo-
synthesis implants, stents, and matrices for tissue engineering. Due to
their application as permanent or temporary implants materials are
differentiated into biostable and biodegradable polymers. The here
identifiedgeneralanduptodaterequirementsforbiomaterialsandthe
illustrated applications in otolaryngology emphasize ongoing research
efforts in this area and at the same time demonstrate the high signifi-
canceofinterdisciplinarycooperationbetweennaturalsciences,engin-
eering, and medical sciences.
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1 Introduction
The tremendous progress in biomaterials research of re-
centyearsinstitutesnewpossibilitiesforthedevelopment
of innovative implants and thus therapeutic options for
diseases lacking appropriate treatment options. Aside
from all technological challenges the selective organiza-
tionofthecell-implantinteractionisofdecisiverelevance.
The implant may be comprised of polymers, metals,
ceramics, or composites (Figure 1). In order to stimulate
tissue regeneration biodegradable polymers can be util-
ized. To improve adhesion and migration of cells struc-
tures could be provided with microporous scaffolds [1],
[2],[3].Shapememorymaterialsmightbeusefultoguide
cellular differentiation and tissue modeling. Polymerme-
diated drug coatings and chemically modified implant
surfaces, combined with nanotechnology, serve as local
drug delivery systems and guide cell growth and other
cellular functions. The terms active agent and drug are
here being used interchangeably.
In the context of drug delivery systems polymer based
drug carriers appear to be suited exceptionally well, be-
causedrugscanbeincludedbysimpleprotocols.Another
advantage is the use of the polymer as a structural com-
ponent of the implant and, at the same time, as local
drug carrier. Biostable polymeric implant materials shall
protect the drugs against metabolic processes but guar-
antee a controlled release of the drug into the host over
a defined period of time.
Embedding biologically active agents into the polymer
coating of a device is one of the options to produce a
local drug delivery system. Polymer solutions containing
the active agent are sprayed onto the implant surface or
applied onto the implant by dip coating. Drugs that are
incorporated into the polymer matrix are released by dif-
fusion or by fragmentation of the polymer provided the
polymer is biodegradable.
An alternative to embedding the active substance in the
polymer is the coupling of the active substance to the
implantsurfaceviachemicalsynthesis(surfaceactivation
andmodification).Chemicaland/orbiologicalinteractions
of the surrounding environment or tissue with the modi-
fied implant surface realize the release of the active
substance. Major targets for local release of biological
active substancesare the specific inhibition of cell prolif-
eration [4], and inflammation [5], and the prevention of
thromboses [6]. A powerful prophylaxis and therapy of
implant associated infections is the local delivery of anti-
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biotics at the implantation site [7]. Another important
topic is the provision of cell specific peptides on the im-
plantsurfaceforpreferentialcelladhesion[8].Moreover,
cellular responses can be influenced through a myriad
ofreceptorsonthecellsurface.Whenappropriatesignal-
ing moleculessuch as growth factors or cytokines[9] are
providedontheimplantsurfacetheattractionofspecific
cells can be controlled.
2 Biomaterials as implant
materials
Generally,biomaterialsarenaturalorsyntheticmaterials
that are utilized in medicinefor therapeuticor diagnostic
purposes and are in direct contact with the tissue of the
organism [10].
These materials interact with the appropriate biological
system. In narrower sense biomaterials signify materials
that remain, as implants, within the organism for longer
periods of time.
The history of biomaterials most likely begins just a few
centuries after Common Era when materials foreign to
the body were used as therapeutic implants. In ancient
medicine biomaterials were applied as rubber soaked
linen for the closure of wounds [11]. From Aztec urial
sites skulls with gold dental fillings were found. Romans
havedescribedtheuseofurologiccatheters.Firstreports
on the applicability of plastics as biomaterial were the
usage of a nylon thread for sutures 1941 and cellulose
hydrate for haemodialysis in 1943. Modern history of
biomaterialscommencesaround1950withthedevelop-
ment of artificial tissues and organs. In 1952 the first
vesselprosthesiswassuccessfullyimplantedinahuman;
this was followed in 1960 by replacement of a mitral
valve by an artificial implant. During the 1960s the area
of research for the development of biomaterials was es-
tablished in order to specifically influence the functional
properties and the biocompatibility of a material to meet
medicalrequirements.Nowadays,biomaterialsarewidely
usedforimplantsinmedicine.Oneexampleareendopros-
theses for joint replacement of chronically inflamed or
worn-out joints. Further examples for the replacement of
organsorpartsoforgansaremechanicandbiologicheart
valve prostheses to treat irreparable heart valve defects,
and intraocular lenses for cataract therapy. Stents serve
to maintain continuity of lumens, for example of blood
vessels,ofurethraandureter,ofthebileduct,wind-pipe,
and esophagus. Cochlear implants are inserted into the
cochlea to stimulate the auditory neurons of deaf or
deafened patients on a routine basis.
2.1Generalandactualrequirementsfor
biomaterials
Biomaterials have to fulfill the following requirements in
order to be suitable as implant materials:
• Technicalfunctionalitythroughmechanicalproperties
tuned to the specific implant
• Sufficient stability against physiological media
• Residue-freemetabolizationforbiodegradablebioma-
terials
• High biocompatibility
• Simple processing
• Sufficiently long shelf-life
• Sterilizable without changes in form and composition
The ideal biomaterial which satisfies all requirements on
functional properties, is entirely biocompatible and thus
canbeapplieduniversallywithpermanentfunctionisnot
available up to now despite tremendous progress on
biomaterials research. Therefore, today’s biomaterials
research will continuously be developed with a focus on
the design of biomaterials surfaces for functional and
biocompatible tissue interaction.
In this context, the use of biomaterials for tissue engin-
eering in otolaryngology is an interesting field of applica-
tion.Availablebiomaterialsmeetfunctionalandbiological
requirementsfortissueengineeringonlypartially.Limita-
tions are found in mechanical properties and in the lack
of inducingwanted cellularreactions.In addition,bioma-
terial cell constructs need to be integrated into the host
tissue to prevent loss of transplanted cells.
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that physicochemical and biophysical properties of the
matrixmaterialsareoptimizedwithchemicalandphysical
methods. Of utmost importance are the size, surface
charge, hydrophilic and hydrophobic properties, as well
as morphology of the material cell/tissue interface. The
choice of the matrix material largely depends on the
particular application site. To provide for optimal thera-
peutic results a large variety of matrix systems is neces-
saryforsurfacefunctionalizationinordertoreleaseactive
agents. In this context, it is advantageous to apply biode-
gradable and bioabsorbable matrix materials which de-
gradecompletelyafterlocalreleaseofactiveagents,and
thus avoid an additional surgical procedure for implant
removal.
3 Polymers as implant materials
A variety of materials can serve as biomaterials. The first
materialsusedasbiomaterialsweremetals.Inparticular
precious metals such as platinum, gold or titanium, also
metal alloys, ceramics, glass, or composites were con-
sidered.Prevalentbiomaterialsarenaturalpolymerssuch
as collagen, alginate, and chitosan as well as synthetic
polymers such as polyethylene, polyethylene terephthal-
ate, and polytetrafluorethylene. Polymers are differenti-
ated into biostable and biodegradable polymers with re-
spect to their application as permanent or temporary
implant materials.
3.1 Biostable polymers
Biostable materials are needed for long term function of
implants. This chapter will focus on biostable polymers
which are considered chemically and biologically inert.
Biostabilityhastobeconsideredwithcautionsincemost
polymers considered as biostable are degraded over the
long run due to the ”aggressive“ physiological conditions
of the human organism. Physical degradation processes
canbeinitiatedby swellingandembrittlementduetothe
elutionofmaterialplasticizers.Also,chemicaldegradation
processes are known. Oxidation of polyether segments
inpolyurethaneattheα-positiontotheether-oxygen[12],
orlongtermhydrolysisofpolyamides[13]orpolyethylene
terephthalate [13], [14] are well documented. These de-
gradation processes proceed over long time periods and
finally lead to a loss of material stability known as mater-
ial fatigue.
Biostablepolymersforlongtermimplantshavetocomply
with implant function within the tissue. They should be
resistant to abrasive wear when used for artificial joints,
showahighmechanicalloadcapacitywhenusedasheart
valve replacement, or possess a high compression
strength and elasticity when used for bone replacement.
Based on implant function the technical requirements
for implant materials are very diverse and should be
realized by the appropriate choice of polymer(s). Proper-
ties of some selected biostable polymers are compiled
in Table 1.
3.2 Biodegradable polymers
Biodegradablebiomaterialsincludechemicalbondswhich
are cleaved under the physiological conditions in an or-
ganism. Therefore, in many cases polymers are used
which containbondsthatcanbe hydrolyzed.Such bonds
are cleaved due to the high content of water within the
human body irrespective of the implantation site.
Moreover,therearechemicalbondswhichcanbecleaved
selectivelybyenzymes.Sinceenzymeconcentrationsvary
considerablywithinanorganism,suchenzymecleavable
bonds are preferentiallyused in polymer biomaterials for
organspecific localdrug delivery applications.Synthetic,
biodegradable polymers are normally degraded non-en-
zymatically by hydrolysis (Table 2), by water mediated
cleavage of the polymer chain to oligomers and finally
monomers [11].
Polymerswhicharedegradedenzymaticallyareprimarily
polypeptides degraded by proteases, polysaccharides
suchasdextranandamylosedegradedbyamylases,and
biopolyesterswhicharedegradedbyesterases(Table3).
P(3HB) one of the biopolyesters has been thoroughly in-
vestigated for its potential as implant material by a
number of research teams. P(3HB) has been shown to
be highly biocompatible and biodegradable. In contrast
tosyntheticallyproducedbiodegradablepolymersP(3HB)
polymer is a highly pure substance lacking impurities
such a remnants of a catalyst or other substances. For
its use in manufacturing medical devices it is highly
relevantthatP(3HB)canbeprocessedwithconventional
technologies [15]. A variety of structures has been pro-
duced for specific medical applications. Porous P(3HB)
patches were developed to substitute for the pericard
[16],[17]ortosealdefectsinthevestibularseptum[18].
Inaddition,P(3HB)sleevesservedashealingsupportfor
tissues and organs [19]. Moreover, it has been shown
that P(3HB) membranes served as mechanical barriers
toprotectorgans,nerves,andtendonsfromnewlyformed
scar tissue [19]. The piezoelectric properties of P(3HB)
makeitaperfectmaterialforneuronalregeneration[20],
[21] which can also be beneficial for bone regeneration.
IthasbeenshownthatP(3HB)compositesstimulatebone
growthandbonehealingprocesses[22].P(3HB)hasalso
beeninvestigatedwithrespecttostentapplications[23],
[24], [25], [26], [27], [28]. Tantalum stents that were
coated with copolymers of 3-hydroxybutyric acid and
3-hydroxyvalericacidwereimplantedinporcinecoronary
arteries. Their biocompatibility was comparable to that
of other synthetic polymer coated stents [26] whereas in
other animal experiments inflammatory reactions have
been reported [27], [28].
The interesting mechanical properties of P(4HB) and the
excellent biocompatibility make it a good material for a
numberofdiversemedicalapplications.P(4HB)suitability
was explored as tissue engineering scaffold for heart
valves [29], [30], vascular patches [31], suture material
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Table 2: Survey on a few important synthetic and biodegradable polymers and their degradation mechanisms, primarily
non-enzymatic hydrolysis.
[32], [33], orthopedic implants [32], [33], stents [32],
[33], [34] and local drug delivery systems [34], [35]. The
advantages of biodegradable implant materials are the
prevention of secondary surgery and foreign body reac-
tions.Anotherbenefitisthatgrowthprocessesparticularly
with children are not hindered.
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4Selectedbiomaterialapplications
in otolaryngology
Inrecentyearsnovelandefficientimplantsbasedonthe
use of innovative biomaterials have been developed for
otolaryngology.Suchimplantsnotonlyreplacedestroyed
tissue or restore physiological functions but also com-
pensate for destroyed sensory or neuronal cells by elec-
trical stimulation, which is feasible by the use of bioma-
terials. One example are the clinically well established
cochlear implants, that allow deaf people with intact
auditory nerves to perceive individual auditory signals
(Chapter4.1).Anotherexampleofbiomaterialapplication
is the surgical repair of facial fractures and bony skull
defects. For stable osteosynthesis nails, screws, plates,
orwiresmanufacturedfromsurgicalstainlesssteel(316L)
or titanium and its alloys are partially replaced by newly
developed biodegradable materials (Chapter 4.2).
Furthermore,stenosesoftheEustachiantubeareamajor
cause of chronic middle ear inflammation with consecu-
tivedestructionofthesoundtransmissionsystem,which
might be cured by an appropriate stent (Chapter 4.3).
Stents might also be used for prevention and treatment
of larynx stenoses and to splint intralaryngeal skin or
mucosa transplants onto larynx defects.
Ofincreasedimportanceinotolaryngologyisthedevelop-
ment of bioartificial tissues by tissue engineering for re-
constructionofepithelia(Chapter4.4).Thecharacteristics
of the scaffold material are crucial for the preservation
and differentiation of the epithelium. These selected ap-
plications will be introduced in more detail in chapters
4.1 to 4.4
4.1 Cochlear implants
The tremendous success story of cochlear implants has
advanced this technology into the clinical routine for the
treatment of deaf born children or deafened adults [36].
Fortheimplantationofthecochlearimplantanelectrode
arrayisplacedintothecochleainsuchawaythatnumer-
ous electrode contacts allow the electrical stimulation of
the auditory nerve. Despite the fact that the technical
developmentof the implant has benefited from the intro-
duction of novel speech processing strategies there are
requirements to the implant that cannot be achieved by
technical improvements. In particular the interface
between electrode and auditory neurons is hampered by
pathophysiologicalprocessesthat can only be controlled
byoptimizedinteractionbetweenelectrodesandneurons.
After cochlear implant insertion fibroblasts migrate into
the scaly tympani and produce fibrous material which
results in increased impedance. On the other hand,
deafnesscausesapartiallossofneuronaldendritessuch
that a large gap between electrodes and auditory nerve
is the consequence. In order to lower the gap between
electrodesandauditoryneuronscurrentresearchfocuses
on the regeneration of auditory neuron dendrites and
preservation of neurons. By local cochlear application of
neurotrophicfactorssuchasglialcell-derivedneurotroph-
ic factor (GDNF) and brain-derived neurotrophic factor
(BDNF) it could be demonstrated in vivo that the number
ofspiralganglionneuronscouldbemaintaned[37],[38].
To reduce fibrosis around the cochlear electrode a single
locally applied dose of glucocorticoids, such as Dexa-
methasone, clearly reduced electrical impedance [39].
In addition, we could show that drug depots can be ac-
commodated in the silicon carrier of the electrodes [40],
[41]. One approach uses cavities that were filled with
Dexamethasone whereas another created polymer-
Dexamethasone-coatings with a smooth surface
(Figure 2).
Investigations on drug release into physiological salt
solution conform that such drug depots can generate
differentdrugreleaseprofiles(Figure3).Dexamethasone
filled cavities rapidly released Dexamethasone over a
short period of time. Incorporation of Dexamethasone in
apolymercoatingresultedinalongtermcontinuousdrug
release. The release of Dexamethasone from polymer
coatings can be adjusted by the polymer type, the Dexa-
methasone amount in the coating, the coating thickness
and lamination, for example by a drug-free polymer top
coat.
Furtherinvestigationswillshowwhetherfunctionalization
of the electrode carrier with antiproliferative drugs or
neurotrophic factors will control fibroblast activity or in-
duce regeneration of auditory neuron dendrites.
Finally, novel concepts are developed that broaden
cochlear implant indications towards a bimodal stimula-
tion of the auditory neurons for patients with severe
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silicone matrix (right).
Figure 3: In vitro release of Dexamethasone from cavities and from polymer coatings with different Dexamethasone contents
(15 and 30 w%) into physiological sodium chloride solution at 37°C.
Figure 4: Endosteal electrode (left) and electrode carrier in a petrosal bone model (right).
amblyacousiatoacousticallystimulatelowerfrequencies
andelectricallyhigherfrequencies.Thereforeitisimpera-
tive to insert the cochlear electrode atraumatically to
preventdamagetointactsensoryhaircellsandneurons.
A novel approach is followed by developing of an en-
dosteal electrode carrier for cochlear stimulation [42],
[43], [44] (Figure 4). A flat electrode carrier is inserted
endosteal thus preserving the fluid filled cavities of the
inner ear and residual hearing.
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4.2 Implants for osteosynthesis at the
bony skull
Plateosteosynthesesallowthreedimensionalreconstruc-
tions of complex face fractures and the skull base with
fortunate aesthetic results. However, these procedures
are sometimes accompanied by infections, sensitivity
perturbations,andthermohyperpathiesinparticularafter
fractures of the frontal sinus which were repaired by im-
plantation of alloplastic permanent materials such as ti-
tanium and titanium alloys and polymethacrylates [45].
Inaddition,titaniumimplantscauseddepositionofabra-
sions in the surrounding tissue which led to removal of
the osseous synthetic material [46]. Other reasons for
secondary surgery for implant removal are implant
translocation, fixation of fractures in growing bones, or
the application of stiff implants in craniofacial surgery
whichleadtogrowthperturbations[47].Toovercomethe
limitations of metallic implants [48] bone replacement
materials were developed from biodegradable polymers
basedonpolyglycolide(PGA),polylactide(PLA)andcopoly-
mers thereof [49], [50], [51]. Such biodegradable bone
replacement systems are preferred for indications in low
strainareasoffacialbonessuchasfixationofboneplates
aftersurgicalintervention,fracturesofthenasoethmoidal
and intraorbital areas, fractures of the sinusoidal wall,
and for reconstruction of craniofacial structures after fa-
cial traumata.
In this context, bone replacement material in form of
osteosynthesisplatesandmembranesmadefromP(3HB)
has been tested. P(3HB) plates including fixation pins
have been utilized for reconstruction of the zygomatic
arch in White New Zealand rabbits (Figure 5).
Macroscopic evaluation showed that the plates were
connate with the bone and the pins firmly fixed in the
bone without a detectable fracture crack. Microscopic
andhistopathologicevaluationshowedthecharacteristic
capsule around the implant, with fibroblasts and macro-
phages,withloosevascularizedconnectivetissueonthe
outside. After increased times after implantation con-
densedcapsularstructureswithnumerouscollagenfibres
were visible. Implant induced benign tumors could be
excluded. Twelve months postoperatively a 3–6% mass
lossoftheP(3HB)implantduedegradationwasobserved
[52].
P(3HB)membranesforduramatersubstitution[53]were
placed subperiostal onto the skullcap of White New Zea-
land rabbits [54] (Figure 5). In the vicinity of the implant
no signs of inflammation could be observed. 20 months
post implantation no macroscopic signs of biomaterial
degradation or absorption were found. 25 months post
implantationthesubperiostalimplanthadvanishedwhich
was interpreted as sign of complete material absorption.
Based on the above observations P(3HB) is well suited
for closure of defects in planar areas of the bony skull,
orforrepairoffractureswithinthefacialareaoftheskull.
The slow degradation of P(3HB) is considered advanta-
geous when compared to that of PLA and PGA [55], [56],
becauseforbonereplacementaslowlydegradingmater-
ial is required [57]. Moreover PGA and PLA are not well
suited for high mechanical loads [58] as the mechanical
strength declines too rapidly due to proceeding material
degradation [59]. Another advantage of P(3HB) are its
piezoelectric properties which are similar to those of
naturalbone[60],[61]andonecanassumethatcompos-
ites based on P(3HB) stimulate bone growth and regen-
eration [62].
4.3 Stents for head and neck
applications
For numerous medical indications stenoses are dilated
minimally invasive and accommodated with a stent. In
interventional cardiology drug-eluting stents (DES) are
applied for the treatment of atherosclerotic vascular dis-
ease [63], [64]. In DES the stent surface is coated with
a drug containing polymer which can be biostable or
biodegradable. In addition to its primary function as
mechanicalsupportofthevesselwall,thestentreleases
drugs locally into the vessel wall [65], [66].
Thistechniquealongwithmicrostructuringofstentsopens
interesting application perspectives in otolaryngology.
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stentsduetothemicroscaleandtheirintelligentsurface.
The modular configuration of such stents comprises the
stent body and the drug depot (Figure 6). Particular re-
quirements have to be met by microstents for treatment
ofEustachiantubedysfunctions[67].Thediameter(<0.5
mm)hastobeconsiderablysmallerthanforcardiovascu-
lar stents (2.5–5 mm), and the permanent opening of
the Eustachian tube should not interfere with the
physiologicalopeningandclosingmechanismduringthe
deglutition process. Stents for the Eustachian tube must
have high mechanical strength and could be produced
from shape memory alloys or polymers.
Figure 6: Principle of a modular Eustachian tube stent with
drug depot for permanent recanalization.
Hence research efforts include the development of the
stent body, and the generation of microporous three-di-
mensional structures which serve valve control and drug
incorporationorcovalentcoupling.Basedontoday’sview,
antibiotics, antiphlogistics, and antiproliferative drugs
are relevant for this particular stent application. Stents
could further be applied for maintenance of the neoost-
ium [68] in modern frontal sinus surgery, prevention and
treatment of laryngeal stenoses, and to splint intralaryn-
geal skin or mucosa transplants.
4.4 Matrix structures for tissue
engineering of epithelia
The generation of bioartificial tissues for reconstruction
ofepitheliathroughtissueengineeringgainssignificance
in otolaryngology. Actual requirements exist to replace
defect or lost respiratory mucosa by novel autologous
equivalents, as there are currently no satisfactory thera-
peutic options to treat extended trachea stenoses. The
currently used alloplastic materials based on silicone or
polypropylene for trachea prostheses show limitations
due to excessive connective tissue growth causing sten-
oses,poortissueintegration,andriskofimplantrejection.
For a successful trachea replacement after trauma or
resection of malign lesions the backing of the implant
with functional respiratory epithelium is imperative.
Another indication is the closure of septum perforations,
which are currently treated surgically with low success
rates.Sincesiliconeobturatorscannotcompletelyresolve
perforationspecificproblems[69]theadaptationofsuch
implants might be achieved by implantation of artificial
polymermatriceswhichareseededwithmucosaspecific
epithelial cells to facilitate adaptation to the biological
tissue and at the same time provide a scaffold and
mechanical support. Numerous in vitro investigations
withrespiratoryepithelialcellswerefocusedonquestions
concerning the function of differentiated and undifferen-
tiated cells and to cultivate respiratory epithelial cells on
various artificial matrices [70], [71], [72]. In animal ex-
perimental models the implantation of membranes or
moulds made of various polymers such as polyethylene
[73], polypropylene [74], polyetherurethanes [75], poly-
tetrafluorethylene [76], collagen [77] and polypropyl-
ene/collagen [78] has been reported. These investiga-
tions were aimed to clarify whether the provided struc-
tureswererepopulatedandwhethertheywoulddifferen-
tiate into tissue like structures. The first trachea replace-
ment in humans using tissue engineering showed that a
polyethylenemeshcoveredwithspongycollagenissuited
tosufficientlyaccommodateacomplicationfreeendotheli-
alization two years post implantation in a 78 year old
patient [79]. Results on the long term behavior of such
trachea constructs are not yet available.
We were able to show that porous matrices (Figure 7)
from the biodegradable polymers PLLA and P(3HB) are
suited for recolonization by human respiratory epithelial
cells [80]. The differentiation of cells could be shown by
the formation of microvilli and in a few cases by the
presence of kinocilia.
Figure 7: Scanning electron micrograph of an open-celled
P(3HB) matrix for tissue engineering of epithelial tissues.
To increase the flexibility of the scaffold materials and to
acceleratedegradationpolymerblendswereinvestigated.
Theblendofpartiallycrystalline,isotacticnaturalP(3HB)
with more than 30% (w) amorphous, atactic, synthetic
P(3HB) resulted in biological incompatibility with numer-
ous dead cells on the scaffold material. Chapter 4 de-
scribesinvitroandinvivoinvestigationswhichshowthat
the material and its characteristics play important roles
formaintenanceanddifferentiationoftheepitheliumand
are the subject of current research in this topic.
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The major interest in biomaterials research is the under-
standing of those cellular mechanisms that guide the
interactionwithbiomaterialsatthematerial/tissueinter-
face. With such knowledge the interaction of cells with
implantmaterialscanbeoptimizedbyshapingthemicro-
andnanostructureoftheimplantsurface.Thefunctional-
izationoftheimplantsurfacebydrugcontainingcoatings
andbychemicalsurfacemodificationsoffertheopportun-
ity of actively govern cellular processes. Such local drug
deliverysystemsfacilitatelocallyandtemporallyrestricted
drug release which has great potential for numerous ap-
plications due to the modular concept. Of equal import-
ance are currently two research trends. One is the drug
targeting and the other the use of micro- and nanotech-
nologiesinbiomaterialsandimplants.Ageneralquestion
regarding biomaterials and implants is the ability of the
implants to grow, regenerate and adapt. Such implant
characteristics will be realized in the future by tissue en-
gineering approaches.
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